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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
15.10.2020 COVID-19 
in 
Pakistan: 
a phone 
survey to 
assess 
education, 
economic, 
and 
health-
related 
outcomes 
CGD | Policy 
paper 
• Using a sample of 1,211 
households in Pakistan, 
authors examine the effects 
of C19 on 3 areas: education, 
economic and health-related 
• While the majority of 
respondents report adopting 
precautionary measures such 
as wearing a face mask 
(90%) and washing their 
hands more often than they 
used to (97%), a vast majority 
of respondents (78%) 
perceive a similar risk of 
contracting C19 or 
tuberculosis, even though 
estimates suggest a 74% 
higher chance of contracting 
C19 compare to TB 
• 68% of respondents 
associate a higher risk of a 
C19 infection if schools 
reopen compared to their 
current perceived risk (in 
June 2020) 
Perception, 
Pakistan 
12.10.2020 Genomic 
evidence 
for 
reinfection 
with 
SARS-
CoV-2: a 
case 
study 
The Lancet 
Infectious 
Diseases 
• Genetic discordance of the 
two SARS-CoV-2 specimens 
from one patient was greater 
than could be accounted for 
by short-term in vivo evolution 
• This suggests that the patient 
was infected by SARS-CoV-2 
on two separate occasions by 
a genetically distinct virus 
• Thus, previous exposure to 
SARS-CoV-2 may not 
guarantee total immunity to 
all cases 
• ALL individuals, whether 
previously diagnosed with 
COVID-19 or not, should take 
identical precautions to avoid 
infection with SARS-CoV-2 
• Reinfection may be relevant 
for vaccine development and 
application 
• Reinfection with SARS-CoV-2 
has now been reported in at 
least four individuals 
worldwide 
reinfection 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary             Keywords 
15.10.2020 Repurposed 
antiviral 
drugs for 
COVID-19 – 
interim WHO 
SOLIDARITY 
trial results 
medRxiv | 
pre-print (not 
peer 
reviewed) 
• For its Solidarity 
clinical trial, WHO 
tested 4 drugs, 
remdesivir, 
hydroxychloroquine, 
auto-immune drug 
interferon and a 
combination of 
lopinavir and 
ritonavir, in 11,266 
adult patients in 
total, across 405 
hospitals in 30 
different countries 
• The remdesivir, 
hydroxychloroquine, 
lopinavir and 
interferon regiments 
appeared to have 
little or no effect on 
hospitalised 
COVID-19 
 Remdesivir, 
hydroxychloroquine, 
interferon, lopinavir 
(mortality, initiation 
of ventilation and 
duration of hospital 
stay) 
• Gilead Sciences Inc 
have dismissed the 
findings  
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
15.10.2020 Safety and 
immunogenicity 
of an 
inactivation 
SARS-CoV-2 
vaccine, 
BBIBP-CorV: a 
randomised, 
double-blind, 
placebo-
controlled, 
phase1/2 trial 
The Lancet 
Infectious 
Diseases | 
Article 
• This is the first report of 
an inactivated SARS-
CoV-2 vaccine tested on 
human participants 
• The inactivated SARS-
CoV-2 vaccine, BBIBP-
CorV, is safe and well 
tolerated at all tested 
doses (2ug, 4ug and 
8ug) in two age groups 
(18-59 years and >=60 
years) 
• Humoral responses 
against SARS-CoV-2 
were induced in all 
vaccine recipients on 
day 42 
• Two-dose 
immunisations with 4ug 
vaccine on days 0 and 
21 or days 0 and 28 
achieved higher 
neutralising antibody 
titres than the single 8ug 
or 4ug doses on days 0 
and 14 
• Further clinical studies 
are warranted to 
evaluate the potential of 
this vaccine in clinical 
application 
Inactivated 
SARS-
CoV-2 
vaccine 
14.10.2020 Safety and 
immunogenicity 
of two RNA-
based Covid-
19 vaccine 
candidates 
NEJM | Article 
• Results of an ongoing, 
placebo-controlled, 
observer-blinded, dose-
escalation phase 1 trial 
of vaccine candidates 
BNT162b1 and 
BNT162b2 
• This data adds to earlier 
interim safety and 
RNA 
vaccine 
immunogenicity data of 
BNT162b1 in younger 
adults from trials in 
Germany and the US 
• The safety and 
immunogenicity data 
from the US phase 1 
trial of two vaccine 
candidates in younger 
and older adults 
supports progressing 
vaccine candidate 
BT162b2 to phase 2-3 
safety and efficacy 
evaluation 
Social Science 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
2020 Clinical and 
vaccine trials 
for COVID-19: 
Key 
considerations 
from social 
science 
SSHAP | Brief 
• This brief sets out 
social science 
considerations that can 
inform clinical and 
vaccine trials for 
COVID-19 
• Considerations 
include: context 
specific research; 
identify community 
dynamics and patterns 
of trust; integrate 
participant and 
community 
perspectives in trial 
design and 
implementation; 
maintain open dialogue 
with participants and 
relevant communities; 
identify sources of 
mistrust and potentials 
for community dialogue 
and respond to them in 
dynamic ways 
Social science 
considerations, 
clinical and 
vaccine trials 
2020 Emerging 
evidence on 
shielding 
vulnerable 
SSHAP | Brief 
• A second briefing, to 
be read in conjunction 
with the first briefing 
which focuses on 
terms and general 
principles, which 
shielding 
groups during 
COVID-19 
focuses on emerging 
evidence (primarily 
from LMIC)  relevant to 
shielding, including 
research regarding 
social acceptability and 
implementation of 
shielding 
• Planning for 
socioeconomic impacts 
on the shielded, 
including psychosocial 
well-being, income 
generation, food 
access and health 
service access is 
essential when 
considering shielding. 
These are trade-offs 
that communities and 
individuals must weigh 
against the positive 
effects of shielding in 
the context of C19 
containment measures 
• Shielding will need to 
be adapted based on 
state and non-state 
capacity to provide 
social and economic 
support for those 
shielding and their 
households and must 
be co-designed with 
target communities 
• Terminology and 
meaning should be 
made clear (confusion 
about differences in 
shielding, quarantine 
and isolation) 
• Mandatory shielding 
policies are unlikely to 
assure compliance 
• Shielding requires 
cross-sectoral 
management 
• Humanitarian 
organisations that 
facilitate shielding 
should do so as part of 
a larger health and 
WASH promotion 
response 
• Ongoing risk analysis 
must be integrated 
within any shielding 
intervention 
• Information and 
support on locally-
appropriate avenues to 
report cases and 
receive emergency 
support after and 
incidence of domestic 
abuse 
Leadership and governance 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
13.10.2020 Community 
engagement 
for COVID-
19 
prevention 
and control: 
a rapid 
evidence 
synthesis 
BMJ Global 
Health | 
Original 
research 
• Community engagement 
has been considered 
fundamental to the 
response to past 
outbreaks 
• There is concern over the 
lack of involvement of 
communities and ‘bottom-
up’ approaches used 
within C19 responses so 
far. This review aims to 
Identify how community 
engagement approaches 
that have been used in 
past epidemics can 
support more robust 
implementation within the 
C19 response – 
particularly in reaching 
marginalised populations 
and to support equity-
informed responses 
• Countries worldwide are 
encouraged to assess 
existing community 
engagement structures 
and use community 
engagement approaches 
to support contextually 
specific, acceptable and 
appropriate COVID-19 
prevention and control 
measures 
Community 
engagement 
Health systems 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
2020 Broader 
health 
impacts of 
vertical 
responses to 
COVID-19 in 
LMICs 
SSHAP | 
Evidence 
Review  
• A review of the effects 
of vertical responses to 
C19 on health systems, 
services, and people’s 
access to and use of 
them in LMICs 
• Here the term ‘vertical 
response’ is used to 
describe decisions, 
measures and actions 
taken solely with the 
purpose of preventing 
and containing C19, 
often without the 
adequate consideration 
of those this affects the 
wider health system and 
pre-existing resource 
constraints 
• Four main sections to 
the review: (1) 
characterising the 
vertical response; (2) 
the drivers of broader 
health impacts; (3) 
evidence of impacts; (4) 
suggestions for 
mitigation 
Health 
impact, 
vertical 
response 
13.10.2020 From overall 
fiscal space 
to budgetary 
space for 
health: 
connecting 
public 
financial 
management 
to resource 
mobilisation 
in the era of 
COVID-19 
CGD | Policy 
paper 
• The budget 
decomposition 
approach presented in 
this paper provides 
insight into the extent to 
which higher public 
expenditure, better 
budget allocations and 
improved public 
financial management 
(PFM) drives expansion 
in budgetary space for 
health 
• The approach is applied 
to 133 LMICs between 
2000-2017 and finds 
that around 70% of 
budgetary space for 
health is driven by 
changes in overall 
public expenditure, 
Public 
financial 
management, 
resource 
mobilisation 
while about 30% is 
directly attributable to 
the share of the budget 
allocated to health 
• A key implication of the 
analysis is that health 
policymakers should 
systematically link PFM 
reforms to budgetary 
space for health by 
supporting 
comprehensive country 
assessments and by 
enhancing the 
effectiveness of budget 
dialogue between 
finance and health 
authorities 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
Nov 2020 Developing health policies in patients presenting 
with SARS-CoV-2: consider tuberculosis  
The Lancet Global Health | 
Comment 
15.10.2020 A promising inactivated whole-virion SARS-
CoV-2 vaccine  
The Lancet Infectious Diseases | 
Comment 
15.10.2020 Bridging Health Gaps with inclusive urbanization  Think Global Health 
15.10.2020 Three lessons from a new phone survey in 
Pakistan  
CGD | Blog 
15.10.2020 Coping with COVID-19: The Pakistan 
Experience  
CGD | Blog 
14.10.2020 Making the $12 billion go further: four things the 
World Bank can do in support of COVID-19 
vaccination efforts  
CGD | Blog 
14.10.2020 Challenges of social health insurance in low- 
and lower-middle income countries: balancing 
limited budgets and pressure to provide 
Universal Health Coverage  
CGD | Blog 
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Dashboards & Trackers 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence 
& policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps WHO Africa Ghana COVID-NMA WHO   FIND SARS-
CoV-2 Test 
Tracker 
  Global 
COVID-19 
Clinical Trial 
Tracker 
  CEPI 
WHO dashboard African 
Arguments 
Indonesia EPPI Centre WHO 
International 
Clinical Trials 
Registry Platform 
(ICTRP) 
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre 
LSHTM 
Johns Hopkins 
University 
European 
CDC 
Nigeria CDC Norwegian 
Institute of 
Public Health 
Cytel  Serology-
based tests for 
COVID-19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF   Sierra 
Leone 
 Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH  Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in Data   Singapore  Our World in 
Data: C19 Policy 
responses 
COVID-evidence       
Global 5050   UK  IFPRI COVID-
19 Policy 
Response Portal 
Cochrane       
CEBM, University of 
Oxford 
  US  COVID-19 
Primer 
Clinicaltrials.gov       
Humanitarian Data 
Exchange 
     NIH LitCovid  UKCDR       
Information is 
Beautiful 
     WHO COVID-
19 Database 
        
LSHTM               
HealthMap (cases)               
The Commons 
Project 
              
SeroTracker               
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y 
C19 Resource Hubs   
Global  Regional 
& Country 
Academic 
journals & 
Publishers 
Institutes/Centres/
Funders/Other 
Health 
Topics 
Social 
Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of the 
WHO 
ICL MRC Centre 
for Global 
Infectious Disease 
Analysis 
Global 
Menstrual 
Collective  
  Disability 
and inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambridge 
University 
Press 
ODI SLH: 
Handwashin
g in low 
resource 
settings 
  Coregroup 
IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell Press Johns Hopkins 
University 
RBM 
Partnership 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academy 
of 
Sciences 
Cochrane  Center for Global 
Development 
 Epidemic 
Preparedne
ss 
Innovations 
  Social 
Development 
Direct C19 
blog series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID 
Repository 
    
UNOCHA OCHA 
Southern 
and 
Eastern 
Africa 
COVID-19 
Digest 
Health Policy 
and Planning  
Norwegian 
Institute of Public 
Health 
    
UNHCR  South 
African 
Governme
nt 
JAMA 
Network 
Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent 
Epidemics  
    
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David 
Nabarro 
  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  
      
Humanitarian 
OpenStreetM
ap Team 
  Wiley       
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Online event 1h30 CGD, GF, AU 
Impact of COVID-19 
across Africa 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 
Online 
courses 
Varies WHO 
Available 
now 
Standard precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 
Johns Hopkins School 
of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
(Geneva 
time) 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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